The Optimer® platform supports a diverse portfolio of partners and technologies.
We work with key partners and projects to generate Optimer® binders that enable these projects on a target-by-target basis. Optimer® binders are currently being developed to enable improved biotherapeutics, diagnostics, and biomanufacturing processes across the life science industry.
We are always interested in supporting new partners via custom development of Optimer® binders for a range of applications. Please get in touch for more details on how we can enable your pipeline and projects.
Aptamer Group is working with Cancer Research UK and Dan Wiseman and the Oglesby Leukaemia Research Programme at the University of Manchester. The project will explore the potential of bifunctional Optimer® therapeutics for the treatment of Chronic Myelomonocytic Leukaemia (CMML) and other myeloid malignancies.
This multi-target agreement with PinotBio will develop Optimer®-drug conjugates for the treatment of different cancer diseases.
Following success of the initial proof-of-concept study, Aptamer Group will develop Optimer® delivery vehicles to non-blood based cancer biomarkers. These will be provided to PinotBio for use with their payload and linker technologies. PinotBio will generate the full Optimer®-drug conjugates and perform initial animal studies to evaluate the conjugate molecules and their potential to progress as clinical candidates.
Both parties will jointly own the developed assets, with each party retaining ownership over the conjugate’s individual components. If successful these therapeutic modalities will open opportunities for downstream value creation in the form of licensing fees, milestones, and or royalties.
Aptamer Group will develop validated Optimer® binders against critical targets for ProAxsis’s diagnostic assays. ProAxsis will then assess Optimer® performance within their current diagnostics assays, with the view to potentially replacing the antibodies in their commercial diagnostic assays.
Aptamer Group will be working in collaboration with ValitaCell to engineer a next-generation platform, in which Optimer® binders enable ValitaCell’s high throughput screening processes to new biologic targets. These screening processes can rapidly identify promising molecules and cell lines that could go on to be developed into new therapeutic drugs.
This partnership will focus on developing new affinity resins to improve the purification and scale-up of gene therapy vectors. Aptamer Group will develop an Optimer® capable of binding and eluting a viral vector. Bio-Works Technologies will then develop a derivatized resin by coupling the Optimer® to its patented WorkBeads™ agarose beads.
As part of this Optimer® binders will be developed, with the potential for incorporation into Takeda’s drug development process.
Following the development of specific Optimer® binders to the agreed range of targets, the Optimer® binders will be available to Takeda to evaluate for the feasibility of working within their internal drug development processes.
Aptamer is working with BaseCure Therapeutics to identify cell targeting Optimer® binders to be developed as potential delivery vehicles to increase siRNA uptake into target cells and tissues.
As part of this partnership Optimer® binders will be developed to several small molecule targets. for incorporation into Flip Gene Therapeutics’ gene therapy platform to support pharmacologically inducible gene therapeutics controllable with a gene switch.
The agreement includes initial upfront payments for Optimer® development, with the potential for further licensing payments for the developed Optimer® binders, and development and commercial milestone payments upon clinical and commercial success.
This partnership will involve the development of Optimer® binders to improve the selectivity and enable multiplex analysis of respiratory vaccine QC assays for Novavax.
Aptamer Group are working with Bioliquid Innovative Genetics S.L. to develop Optimer® binders that will enable a novel prenatal and placental diagnostic platform.
Multiple contracts are in progress with a top five pharmaceutical company to develop Optimer® binders as immunohistochemistry reagents to support both pipeline assets and early discovery targets.
This therapeutic partnership involves the development of Optimer® binders to block the activity of naturally occurring antibodies within the body for use as a potential therapy to prevent transplant rejection. The Optimer® binders may then support the development of a companion diagnostic panel, in addition to therapeutic use.
